A Validation Study for Recurrence Risk Stratification of Stage II Colon Cancer Using the 55-Gene Classifier
A Validation Study for Recurrence Risk Stratification of Stage II Colon Cancer Using the 55-Gene Classifier
复制标题
DOI：
10.1159/000506369
复制
发表时间：
2020-08-01
期刊：
影响因子：
3.5
通讯作者：
Hase, Kazuo
中科院分区：
文献类型：
--
作者：
Shinto, Eiji;Oki, Eiji;Hase, Kazuo
前言：DNA微阵列，例如使用>；600基因的共识分子亚型(CMS)分类，被用于预测癌症患者的预后。我们最近构建了一个简单的55基因分类器(55GC)系统来对结肠癌(CC)进行风险分层。目的：我们验证了针对II期CC的55GC，并将其与CMS分类进行了比较。方法：对从2009至2012年间接受根治性手术但未进行辅助化疗的232例II期CC患者的组织切片进行DNA芯片分析。结果：根据55GC将患者分为微卫星不稳定亚型(27%)、染色体不稳定亚型(41%)和间质亚型(32%)，5年无复发生存率(RFS)分别为88.5、83.3、71.2%(间质与其他：P=0.0049)。Cox比例风险模型的多因素分析显示，间质亚型PT4和所检查的淋巴结数目(
Introduction:DNA microarrays, such as the consensus molecular subtype (CMS) classification using >600 genes, are used to predict cancer patient prognosis. We recently constructed a simple 55-gene classifier (55GC) system to risk stratify colon cancer (CC).Objective:Here, we validate the 55GC specifically for stage II CC and compare it with CMS categories.Methods:Tissue sections from 232 stage II CC patients who underwent curative surgery without adjuvant chemotherapy between 2009 and 2012 were subjected to DNA microarray analysis.Results:Based on the 55GC, patients were classified into microsatellite instability-like (27%), chromosomal instability-like (41%), and stromal (32%) subtypes with 5-year relapse-free survival (RFS) rates of 88.5, 83.3, and 71.2%, respectively (stromal vs. others:p= 0.0049). Multivariate analysis by Cox's proportional hazard model revealed that the stromal subtype, pT4, and the number of lymph nodes examined (